Pfizer, Inc.
PFE · NYSE · USD
$27.82
−0.18 −0.64%todayNot financial advice.
- Open
- 27.90
- Day range
- 27.48 - 28.00
- 52-week range
- 23.62 - 29.21
- Volume
- 44.43M
- Market cap
- 158.56B
- P/E ratio
- 36.84
- EPS
- 0.76
- Dividend yield
- 6.18%
- Beta
- 0.44
Performance
W
−2.20%
1M
−0.70%
3M
+14.27%
6M
+1.83%
YTD
+11.37%
Y
+5.30%
5Y
−34.89%
All
+6,376.79%
In the news
Oct 9
Starbucks and RPM Boost Quarterly Dividends as Ex-Dividend Dates Approach
Several major companies announced dividend increases and declarations, while others prepare for upcoming ex-dividend dates next week.
Dividends
Oct 8
FDA Approves Pfizer's Tukysa Combination for Frontline Maintenance of HER2-Positive Breast Cancer
Pfizer received FDA approval for a Tukysa combination to treat HER2-positive breast cancer, expanding its oncology portfolio and frontline options.
Company news
Oct 8
Cantor Fitzgerald Raises Price Targets for Eli Lilly, Pfizer, and Merck
Cantor Fitzgerald raised price targets for Eli Lilly, Pfizer, and Merck, highlighting drug pipelines and growth prospects.
Analyst ratings
Oct 8
Pfizer to Cut 330 Jobs and Close Penicillin Unit at Italian Plant
Pfizer Inc. will close its penicillin department and lay off 330 workers at its Catania plant in Sicily as part of a restructuring plan.
Company news
Oct 7
FDA Approves Pfizer Breast Cancer Drug Combination for First-Line Maintenance Therapy
Pfizer's TUKYSA regimen won FDA approval as a first-line maintenance treatment for metastatic breast cancer, delaying disease progression.
Company news
Oct 7
FDA Approves Pfizer's Tukysa Combination for Front-Line Breast Cancer Treatment
The FDA approved Pfizer's Tukysa combination regimen for front-line breast cancer treatment, expanding the drug's market reach.
Company news
Oct 7
FDA Approves Pfizer's TUKYSA Combination for Front-Line Metastatic Breast Cancer
Pfizer's TUKYSA combination has been approved by the FDA as a front-line maintenance therapy to delay disease progression in HER2-positive breast cancer.
Company news
Oct 7
Pfizer Wins FDA Approval for TUKYSA as Front-Line Breast Cancer Maintenance Treatment
Pfizer (PFE) secured FDA approval for TUKYSA as a front-line breast cancer maintenance therapy, expanding its oncology revenue potential.
Company news
Embed on your site
Embed docsAdd a live price card or a chart to any page. Free, no sign-up; cards refresh every minute and link back here.
<iframe src="https://stocks.freetheai.org/embed/NYSE-PFE" width="340" height="170" style="border:0;max-width:100%" loading="lazy" title="Pfizer, Inc. (PFE) - FreeTheAI Stocks"></iframe>
<p style="font-size:12px"><a href="https://stocks.freetheai.org/symbols/NYSE-PFE">PFE stock price</a> by FreeTheAI Stocks</p>